There are currently 1494 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
NCT05796375
Recruiting
The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, complications, cancer recurrence or cancer progression when some cystoscopy procedures are replaced with urine testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770
Recruiting
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
05/13/2025
Locations: UT Southwestern/Children's Health, Dallas, Texas
Conditions: Dravet Syndrome
Register for Updates
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797
Recruiting
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
05/13/2025
Locations: Baylor Scott & White Research Institute, Dallas, Texas
Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
Register for Updates
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652
Recruiting
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/13/2025
Locations: Research Site, Dallas, Texas +1 locations
Conditions: Heart Failure and Impaired Kidney Function
Register for Updates
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686
Recruiting
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/13/2025
Locations: Baylor Scott & White Research Institute, Dallas, Texas
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
NCT05900050
Recruiting
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Failure, ACLF) and accumulation of fluid in the abdominal cavity (ascites)
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
05/13/2025
Locations: The Liver Institute at Methodist Dallas, Dallas, Texas
Conditions: Acute-On-Chronic Liver Failure, Ascites
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT06850922
Recruiting
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Texas Retina Associates, Dallas, Texas
Conditions: Diabetic Macular Edema
Register for Updates
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
NCT06854952
Recruiting
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/13/2025
Locations: FALCON Research Site, Dallas, Texas
Conditions: Overweight or Obesity
Register for Updates
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
NCT04349436
Recruiting
This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malign... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma
Register for Updates
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
NCT06924021
Recruiting
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/13/2025
Locations: Retina Foundation of the Southwest, Dallas, Texas
Conditions: Age-Related Macular Degeneration
Register for Updates
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: The University of Texas, Southwestern Medical Center, Dallas, Texas
Conditions: Peripheral Vascular Diseases
Register for Updates
A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
NCT05911763
Recruiting
This is a prospective, observational, multi-center longitudinal cohort study to describe the real-world effectiveness, safety and treatment usage of efanesoctocog alfa in patients with hemophilia A treated per standard of care in the US and Japan. Patients will be enrolled in the study after the introduction of efanesoctocog alfa in the hemophilia treatment landscape in each study country. Decision to initiate treatment with commercially available efanesoctocog alfa will be made by the treating... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/13/2025
Locations: University of Texas Southwestern Medical Center-2001 Inwood Rd- Site Number : 8400020, Dallas, Texas +1 locations
Conditions: Hemophilia A
Register for Updates